Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Oral Βglucan

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06057948Phase 2Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT02043899Phase 1/2CompletedPrimary

A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma

Showing all 2 trials

Research Network

Common Treatments

  • Oral Βglucan1
  • Opt821 Qs211
  • 124imetaiodobenzylguanidine1

Active Sponsors

  • Memorial Sloan Kettering Cancer Center1
  • Cancer Research UK1

Top Investigators

Related Conditions

  • Neuroblastoma1
  • Highrisk Neuroblastoma1

Activity Timeline